Prof Nicolas Girard speaks to ecancer about the event-free survival (EFS) results from the phase 3 CheckMate 816 trial. This trial investigated Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC).

He initially talks about the background and methodology of the trial. The Phase 3 CheckMate -816 trial showed that neoadjuvant treatment with three cycles of nivolumab in combination with chemotherapy significantly improved event-free survival (EFS), a primary endpoint, compared to chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC).

With a minimum follow-up of 21.0 months, Nivolumab with chemotherapy reduced the risk of disease recurrence, progression or death by 37% across randomised patients when administered before surgery.

In patients receiving the combination, median EFS was 31.6 months, compared to 20.8 months for patients treated with chemotherapy alone.

Prof Girard explains the results from this trial and how they can impact the future treatment of NSCLC.